Evidence map›Paper›PMID 34344402›Full record

Trial reportRadiation oncology (London, England)2021

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer.

Nicholas Hardcastle, Olivia Cook, Xenia Ray, Alisha Moore, Kevin L Moore, David Pryor, Alana Rossi, Farshad Foroudi, Tomas Kron, Shankar Siva

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Nicholas HardcastlePhysical Sciences, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. nick.hardcastle@petermac.org.ORCID http://orcid.org/0000-0001-7796-8472
Olivia CookTrans Tasman Radiation Oncology Group, Newcastle, Australia.
Xenia RayDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, USA.
Alisha MooreTrans Tasman Radiation Oncology Group, Newcastle, Australia.
Kevin L MooreDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, USA.
David PryorDepartment of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.
Alana RossiTrans Tasman Radiation Oncology Group, Newcastle, Australia.
Farshad ForoudiOlivia Newton, John Cancer Centre at Austin Health, Heidelberg, Australia.
Tomas KronPhysical Sciences, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Shankar SivaDepartment of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, Australia.ORCID https://orcid.org/0000-0003-2840-0658
Trans Tasman Radiation Oncology Group · AUThe University of Melbourne · AUUniversity of California San Diego · USOlivia Newton-John Cancer Wellness & Research Centre · AUPrincess Alexandra Hospital · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionQuality assurance (QA) of treatment plans in clinical trials improves protocol compliance and patient outcomes. Retrospective use of knowledge-based-planning (KBP) in clinical trials has demonstrated improved treatment plan quality and consistency. We report the results of prospective use of KBP for real-time QA of treatment plan quality in the TROG 15.03 FASTRACK II trial, which evaluates efficacy of stereotactic ablative body radiotherapy (SABR) for kidney cancer.

methodsA KBP model was generated based on single institution data. For each patient in the KBP phase (open to the last 31 patients in the trial), the treating centre submitted treatment plans 7 days prior to treatment. A treatment plan was created by using the KBP model, which was compared with the submitted plan for each organ-at-risk (OAR) dose constraint. A report comparing each plan for each OAR constraint was provided to the submitting centre within 24 h of receiving the plan. The centre could then modify the plan based on the KBP report, or continue with the existing plan.

resultsReal-time feedback using KBP was provided in 24/31 cases. Consistent plan quality was in general achieved between KBP and the submitted plan. KBP review resulted in replan and improvement of OAR dosimetry in two patients. All centres indicated that the feedback was a useful QA check of their treatment plan.

conclusionKBP for real-time treatment plan review was feasible for 24/31 cases, and demonstrated ability to improve treatment plan quality in two cases. Challenges include integration of KBP feedback into clinical timelines, interpretation of KBP results with respect to clinical trade-offs, and determination of appropriate plan quality improvement criteria.

Indexed as

Follow-Up StudiesHumansKidney NeoplasmsKnowledge BasesOrgans at RiskPrognosisProspective StudiesRadiosurgeryRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedClinical trialKidneyKnowledge based planningQuality assuranceRenal cell carcinomaSABRSBRT

Identifiers

PMID34344402
PMCPMC8330099
OpenAlexW3187092739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.